GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
F

Foresee Pharmaceuticals Co 6576.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

73.90

+2.78%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

About Foresee Pharmaceuticals Co

Its shares trade on Taipei Exchange under the ticker 6576.TWO. It has been listed since 12 April 2016. In the fiscal year to 31 December 2025, it reported revenue of TWD 431.3m and a net loss of TWD 883.2m. At that date it held total assets of TWD 1.31bn and shareholders' equity of TWD 929.6m.

Foresee Pharmaceuticals Co., Ltd., is a clinical-stage pharmaceutical company, which engages in the pharmaceutical and drugs distribution. The company is headquartered in Taipei City, Taipei. The company went IPO on 2016-04-12. The firm's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. The company also engages in new pharmaceuticals clinic trial business.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
12 Apr 2016
Website
foreseepharma.com ↗

Leadership

Pay as last reported

  • Mr. Benjamin ChienChairman of the Board, General Manager, since 2013TWD 2.7m
  • Mr. Meng Kung ChanChief Financial Officer, Corporate Governance Officer
  • Mr. Mathieu BoudreauChief Operating Officer, Chief Business Officer
  • Mr. Yuhua LiChief Technology Officer
  • Mr. Wenjin YangChief Scientific Officer
  • Mr. Bassem ElmankabadiSenior Deputy General Manager-Clinical Development
  • Mr. William MillerDeputy General Manager-Regulatory Affairs
  • Mr. Jagdish ParasrampuriaSenior Deputy General Manager-CMC & Manufacturing
  • Mr. Yisheng LeeChief Medical Officer, Director, since 2013
  • Ms. Ruby ChenAccounting Manager
  • Mr. Jia-Long LeeDirectorTWD 80,000
  • Mr. Jeff WangDirectorTWD 64,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Foresee Pharmaceuticals' FP-001 targets prostate cancer with clinical-stage development.
  • FP-025 addresses asthma and COPD in the respiratory treatment segment.
  • The company's IPO on 12 April 2016 provided initial capital for R&D.

Weaknesses

  • The company focuses solely on clinical-stage pharmaceuticals without commercialized products.
  • Limited product portfolio with only two main drugs FP-001 and FP-025.
  • No mention of international markets or global distribution channels.

Opportunities

  • Expanding FP-025 into the growing respiratory disease treatment market in Asia.
  • Potential partnerships for FP-001 in prostate cancer therapy markets.
  • Increasing demand for new pharmaceuticals in the Health Care sector.

Threats

  • Competition from established pharmaceutical companies in the Health Care sector.
  • Regulatory challenges in clinical trials for FP-001 and FP-025.
  • Dependence on single product development stages without diversification.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.